公开(公告)号：US20170128593A1

公开(公告)日：2017-05-11

申请号：US15206329

申请日：2016-07-11

Applicant: NATIONAL CHENG KUNG UNIVERSITY

Inventor： Yee-Shin LIN ,  Yu-Hung CHEN

IPC: A61K39/193 ,  A61K39/12 ,  C12N7/00

CPC classification number: A61K47/6939 ,  A61K39/12 ,  A61K39/39 ,  A61K47/6921 ,  A61K47/6933 ,  A61K47/6935 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55583 ,  A61K2039/6031 ,  A61K2039/6093 ,  A61K2039/622 ,  A61K2039/64 ,  C12N7/00 ,  C12N2770/24134 ,  Y02A50/386

Abstract: The present invention relates to an immunostimulatory nanocomplex. The immunostimulatory nanocomplex comprises polyglutamic acid (PGA), a first positively charged substance, a second positively charged substance and a dengue viral protein for holding the dengue viral protein inside. The immunostimulatory nanocomplex is characterized by having a nonuniformally and positively charge distribution along a radial direction thereof. The nonuniformally and positively charge distribution comprises a first electrically charged portion having substantially electrical neutrality, a second electrically charged portion surrounding the first electrically charged portion, and a third electrically charged portion surrounding the second electrically charged portion. The third electrically charged portion has a third volume charge density more than a second volume charge density of the second electrically charged portion, thereby enhancing CD8(+) T-cell response and higher antibody titer after administrating an organism with the immunostimulatory nanocomplex.

公开(公告)号：US09642903B2

公开(公告)日：2017-05-09

申请号：US13384286

申请日：2010-07-15

Applicant: Lior Carmon

Inventor： Lior Carmon

IPC: A61K39/12 ,  A61K39/00 ,  A61K31/04 ,  A61K39/09 ,  A61P37/04 ,  A61K39/04

CPC classification number: A61K39/04 ,  A61K2039/6031 ,  A61K2039/6068 ,  A61K2039/6075 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/414

Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.

公开(公告)号：US20170112910A1

公开(公告)日：2017-04-27

申请号：US15299993

申请日：2016-10-21

Applicant: Korea University Research And Business Foundation ,  Korea Institute of Science and Technology

Inventor： Jeewon Lee ,  Bo Ram Lee ,  Kwangmeyung Kim ,  Ju Hee Ryu ,  Ho Kyung Ko

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K9/5169 ,  A61K2039/55555 ,  A61K2039/6031 ,  B82Y5/00

Abstract: The present invention relates to a protein nanoparticle having a surface on which a cancer-specific epitope is fused and expressed, a method for producing the same, and a composition for cancer immunotherapy containing the protein nanoparticle as an active ingredient, and more specifically, to a recombinant microorganism into which a vector in which a promoter, a gene of a human ferritin heavy chain protein, and a gene encoding the cancer-specific epitope are operably linked is introduced, a protein nanoparticle in which a cancer-specific epitope is fused and expressed on a surface of the human ferritin heavy chain protein, a method of producing the protein nanoparticle, and a composition for cancer immunotherapy including the protein nanoparticle as the active ingredient, wherein the cancer-specific epitope on the surface of the protein nanoparticle according to the present invention is able to be expressed with correct orientation and high density, and the composition for cancer immunotherapy including the protein nanoparticle as the active ingredient has significantly excellent cancer immunotherapeutic effect as compared to the existing nanoparticle-based composition.

公开(公告)号：US20170106083A1

公开(公告)日：2017-04-20

申请号：US14884415

申请日：2015-10-15

Applicant: Joseph Gerard Birmingham

Inventor： Joseph Gerard Birmingham

IPC: A61K39/385 ,  A61K39/00 ,  B03C11/00 ,  B03C5/02 ,  B03C5/00

CPC classification number: A61K39/385 ,  A61K39/00 ,  A61K2039/6031 ,  A61K2039/6043 ,  B03C5/005 ,  B03C5/026 ,  B03C2201/26

Abstract: A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (CPAC) using insulator-dielectrophorsis (i-DEP)-based devices. The ionized gas uniquely forms more and varied chaperone proteins and chaperone protein-antigen complexes (CPAC) than prior art mechanical, chemical, electric or other lysing techniques. These CPAC generated by the ionized gas lysis and separated by i-DEP are electrospray-encapsulated by a biodegradeable polymer at the nano particle level to further enhance these personalized vaccines for accelerated immune system uptake. For the first time, sterile eradication of infectious pathogens and cancer (known or unknown to exist in the host) can be accomplished with multiple personalized vaccine treatments.

公开(公告)号：US20170100466A1

公开(公告)日：2017-04-13

申请号：US15388398

申请日：2016-12-22

Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN ,  LIFE SCIENCES RESEARCH PARTNERS VZW

Inventor： Jean-Marie SAINT-REMY

IPC: A61K39/00

CPC classification number: A61K39/001 ,  A61K39/00 ,  A61K39/0005 ,  A61K2035/122 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/6031 ,  C07K14/755 ,  C07K2319/00 ,  C12N9/0036

Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a soluble allofactor and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore.

公开(公告)号：US20170049898A1

公开(公告)日：2017-02-23

申请号：US15242682

申请日：2016-08-22

Applicant: ALTIMMUNE UK LIMITED

Inventor： Dominique Bonnet ,  Carlton B. Brown ,  Bertrand V. Georges ,  Philip J. Sizer

IPC: A61K47/48 ,  A61K39/145

CPC classification number: A61K47/58 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K39/385 ,  A61K47/54 ,  A61K47/646 ,  A61K2039/54 ,  A61K2039/55511 ,  A61K2039/60 ,  A61K2039/6018 ,  A61K2039/6031 ,  C07K14/005 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16222 ,  C12N2760/16322

Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Abstract translation: 本发明涉及用于将流感抗原递送至免疫反应性靶细胞的碳氟载体。 它进一步涉及氟碳载体 - 流感抗原构建体，以及在动物（包括人）中使用与抗原相关的载体作为疫苗和免疫治疗剂。

公开(公告)号：US20160375123A1

公开(公告)日：2016-12-29

申请号：US15262268

申请日：2016-09-12

Applicant: The Government of the U.S.A. as rep. by the Secretary of the Department of Health and Human Se

Inventor： Gwong-Jen J. Chang ,  Wayne D. Crill ,  Holly R. Hughes ,  Brent S. Davis

IPC: A61K39/12 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6075 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/24122 ,  C12N2770/24123 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24171 ,  Y02A50/386

Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.

Abstract translation: 本文描述的是具有消除与免疫增强相关的免疫优势交叉反应性表位的突变的登革病毒E-糖蛋白多肽。 所公开的登革热病毒E-糖蛋白任选地还包括引入强CD4T细胞表位的突变。 公开的E-糖蛋白多肽或编码多肽的核酸分子可用于例如针对登革热病毒的单价或四价疫苗。

公开(公告)号：US20160367653A1

公开(公告)日：2016-12-22

申请号：US15256683

申请日：2016-09-05

Applicant: The Regents of the University of California

Inventor： Leonard H. Rome ,  Valerie A. Kickhoefer ,  Sherven Sharma ,  Steven M. Dubinett ,  Isaac Yang ,  Linda M. Liau ,  Kathleen A. Kelly ,  Jian Yang ,  Upendra K. Kar ,  Cheryl Champion ,  Janina Jiang

IPC: A61K39/00 ,  A61K38/19 ,  A61K38/45

CPC classification number: A61K39/0011 ,  A61K9/5052 ,  A61K38/177 ,  A61K38/19 ,  A61K38/195 ,  A61K38/45 ,  A61K47/646 ,  A61K47/6925 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6081 ,  A61K2039/64 ,  A61K2039/645 ,  C07K14/00 ,  C07K14/77 ,  C07K2319/00 ,  C07K2319/01 ,  C12N2710/14043 ,  C12Y204/0203

Abstract: The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.

公开(公告)号：US09512181B2

公开(公告)日：2016-12-06

申请号：US14122850

申请日：2012-05-29

Applicant: Theodore G. Clark ,  Yelena Bisharyan ,  Ashot Papoyan ,  Kyle Anderson ,  Paul Colussi

Inventor： Theodore G. Clark ,  Yelena Bisharyan ,  Ashot Papoyan ,  Kyle Anderson ,  Paul Colussi

IPC: C07K14/00 ,  C07K14/435 ,  A61K39/385 ,  C07K14/44 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K14/00 ,  A61K39/385 ,  A61K45/06 ,  A61K2039/6031 ,  A61K2039/62 ,  C07K14/435 ,  C07K14/44 ,  C07K2319/00 ,  C07K2319/04 ,  C07K2319/21 ,  C07K2319/40 ,  C07K2319/42 ,  C07K2319/50

Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production of immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Granule lattice protein/Antigen(Grl/Ag) fusion polypeptides.

Abstract translation: 本发明涉及生产免疫原性颗粒的方法。 在某些实施方案中，本发明涉及用于生产纤毛虫中产生的免疫原性颗粒的方法和产品。 在某些实施方案中，本发明涉及包含颗粒晶格蛋白/抗原（Gr1 / Ag）融合多肽的组合物。

公开(公告)号：US09475853B2

公开(公告)日：2016-10-25

申请号：US14373212

申请日：2013-01-22

Applicant: ALBANY MEDICAL COLLEGE

Inventor： Karsten Hazlett ,  Edmund Gosselin ,  Timothy Sellati ,  Tiffany Zarrella

IPC: A61K39/02 ,  C07K14/47 ,  C07K14/195 ,  A61K39/00

CPC classification number: C07K14/472 ,  A61K39/0208 ,  A61K39/0291 ,  A61K2039/53 ,  A61K2039/6031 ,  C07K14/195 ,  C07K2319/00 ,  C07K2319/33 ,  Y02A50/401 ,  Y02A50/405

Abstract: Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side effects. As a consequence, vaccine discovery is often slow, inefficient, and unsuccessful in the case of many high priority pathogens. The present disclosure suggests that vaccine generation for bacterial pathogens can be improved by optimizing the efficiency of processing/presentation of a bacterial immunogen via the targeting of immunogen to CR2 and/or TLR2 on APCs. This approach not only yields an adjuvant-free mucosal vaccine against a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly impacting preventive medicine/public health.

Abstract translation: 制定有效和统一的疫苗发展战略是征服目前和新出现的传染病的关键。 尽管针对一系列细菌试剂取得了成功，但目前疫苗开发的方法与其目标的微生物一样多样，并且需要通常具有有限功效和/或毒性副作用的佐剂。 因此，在许多高优先级病原体的情况下，疫苗发现通常是缓慢，低效率和不成功的。 本公开内容表明，通过在APC上通过将免疫原靶向CR2和/或TLR2来优化处理/呈递细菌免疫原的效率，可以改善细菌病原体的疫苗产生。 这种方法不仅产生针对A类生物降解剂的无佐剂的粘膜疫苗，而且建立了疫苗开发的新型遗传方法/平台，适用于许多其他感染因子，从而深刻影响预防医学/公共卫生。